Bioethics established itself in the late 1960s as a field concerned with the ethical and philosophical implications of certain biological and medical procedures, technologies, and treatments. Early issues included end-of-life decision-making, organ donation, and human experimentation. Human biotechnology became a concern when the first bioethics institutes were established in the early 1970s. This attention skyrocketed in 1990 when the U.S. Human Genome Project earmarked 3% to 5% of its $3 billion federal budget to the Ethical, Legal, and Social Implications (ELSI) research program, making its activities the world's largest bioethics program.
Bioethics initially represented diverse ethical philosophies. But by the mid-1980s, most professional bioethicists were grounded in individualist and utilitarian frameworks. Bioethicists appropriately continued to consider informed consent, patient safety and similar topics, but their attention to the broad social and political meanings of human biotechnologies had faded.
This shift has been unfortunate for the public's understanding. Most bioethicists present themselves as disinterested analysts who can be trusted to represent a full range of constituencies: researchers, biotech corporations, patients, religious groups, marginalized communities, and other affected parties. But in fact, many promote their own world views, which often emphasize libertarian values over commitments to the public interest.
The role of bioethics has been further compromised by its increasing financial and professional ties to the biotech industry. Many university bioethics centers receive funding from biotech corporations, and many bioethicists serve as paid or unpaid members of corporate "ethical advisory boards."
Blame bad incentives for bad scienceby Bethany Berkshire, ScienceNewsOctober 21st, 2016The publish-or-perish culture promotes high-impact papers with novel findings, ultimately leading to sloppy, irreproducible, and sometimes unethical practices.
Just What We Need: Slicker Infertility Marketingby Gina Maranto, Biopolitical Times guest contributorOctober 21st, 2016A serial tech entrepreneur launches a new start-up called Prelude with a hipster-chic website downplaying the many unknowns of egg freezing.
Social science: Include social equity in California Biohubby Science FARE (Feminist Anti-Racist Equity) Collective: Jessica Cussins, Kate Weatherford Darling, Ugo Edu, Laura Mamo, Jenny Reardon & Charis Thompson, NatureOctober 19th, 20165–7% of the Chan-Zuckerberg Initiative's Biohub health-research budget should be used to design and monitor goals of justice and equality from the outset, or social inequalities could limit the project's potential.